Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 11 06 2019
accepted: 06 10 2019
pubmed: 7 11 2019
medline: 10 4 2021
entrez: 7 11 2019
Statut: ppublish

Résumé

Conflicting evidence exists on the complication rates after cystectomy following previous radiation (pRTC) with only a few available series. We aim to assess the complication rate of pRTC for abdominal-pelvic malignancies. Patients treated with radical cystectomy following any previous history of RT and with available information on complications for a minimum of 1 year were included. Univariable and multivariable logistic regression models were used to assess the relationship between the variable parameters and the risk of any complication. 682 patients underwent pRTC after a previous RT (80.5% EBRT) for prostate, bladder (BC), gynecological or other cancers in 49.1%, 27.4%, 9.8% and 12.9%, respectively. Overall, 512 (75.1%) had at least one post-surgical complication, classified as Clavien ≥ 3 in 29.6% and Clavien V in 2.9%. At least one surgical complication occurred in 350 (51.3%), including bowel leakage in 6.2% and ureteric stricture in 9.4%. A medical complication was observed in 359 (52.6%) patients, with UTI/pyelonephritis being the most common (19%), followed by renal failure (12%). The majority of patients (86%) received an incontinent urinary diversion. In multivariable analysis adjusted for age, gender and type of RT, patients treated with RT for bladder cancer had a 1.7 times increased relative risk of experiencing any complication after RC compared to those with RT for prostate cancer (p = 0.023). The type of diversion (continent vs non-continent) did not influence the risk of complications. pRTC carries a high rate of major complications that dramatically exceeds the rates reported in RT-naïve RCs.

Identifiants

pubmed: 31691084
doi: 10.1007/s00345-019-02982-6
pii: 10.1007/s00345-019-02982-6
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1959-1968

Investigateurs

Evanguelos Xylinas (E)
Michael Rink (M)

Références

Stein JP, Lieskovsky G, Cote R et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675. https://doi.org/10.1200/jco.2001.19.3.666
doi: 10.1200/jco.2001.19.3.666 pubmed: 11157016
Novara G, De Marco V, Aragona M et al (2009) Complications and mortality after radical cystectomy for bladder transitional cell cancer. J Urol 182:914–921. https://doi.org/10.1016/j.juro.2009.05.032
doi: 10.1016/j.juro.2009.05.032 pubmed: 19616246
Shabsigh A, Korets R, Vora KC et al (2009) Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 55(1):164–176. https://doi.org/10.1016/j.eururo.2008.07.031
doi: 10.1016/j.eururo.2008.07.031 pubmed: 18675501
Chang SS, Alberts GL, Smith JA, Cookson MS (2004) Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol 22(4):272–276. https://doi.org/10.1007/s00345-004-0446-4
doi: 10.1007/s00345-004-0446-4 pubmed: 15448995
Eisenberg MS, Dorin RP, Bartsch G, Cai J, Miranda G, Skinner EC (2010) Early complications of cystectomy after high dose pelvic radiation. J Urol 184(6):2264–2269. https://doi.org/10.1016/j.juro.2010.08.007
doi: 10.1016/j.juro.2010.08.007 pubmed: 20952024
Eswara JR, Efstathiou JA, Heney NM et al (2012) Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol 187(2):463–468. https://doi.org/10.1016/j.juro.2011.09.159
doi: 10.1016/j.juro.2011.09.159 pubmed: 22177159
Nguyen DP, Awamlh Al Hussein Al, Faltas BM et al (2015) Radical cystectomy for bladder cancer in patients with and without a history of pelvic irradiation: survival outcomes and diversion-related complications. Urology 86(1):99–107. https://doi.org/10.1016/j.urology.2015.02.061
doi: 10.1016/j.urology.2015.02.061 pubmed: 26142590
Ramani VAC, Maddineni SB, Grey BR, Clarke NW (2010) Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis. Eur Urol 57(6):1058–1063. https://doi.org/10.1016/j.eururo.2009.12.002
doi: 10.1016/j.eururo.2009.12.002 pubmed: 20022162
Yee DS, Shariat SF, Lowrance WT et al (2010) Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. J Urol 183(5):1751–1756. https://doi.org/10.1016/j.juro.2010.01.014
doi: 10.1016/j.juro.2010.01.014 pubmed: 20299035 pmcid: 4295901
Nieuwenhuijzen JA, Horenblas S, Meinhardt W, van Tinteren H, Moonen LMF (2004) Salvage cystectomy after failure of interstitial radiotherapy and external beam radiotherapy for bladder cancer. BJU Int 94(6):793–797. https://doi.org/10.1111/j.1464-410X.2004.05034.x
doi: 10.1111/j.1464-410X.2004.05034.x pubmed: 15476510
Edsmyr F, Moberger G, Wadström L (1971) Carcinoma of the bladder. Cystectomy after supervoltage therapy. Scand J Urol Nephrol 5(3):215–221. http://www.ncbi.nlm.nih.gov/pubmed/4998747 . Accessed 12 Jan 2018
Lund F (1980) Cystectomy following full course irradiation. Bladder tumors and other topics in urological oncology. Springer, Boston, pp 287–289. https://doi.org/10.1007/978-1-4613-3030-1_56
doi: 10.1007/978-1-4613-3030-1_56
Mitropoulos D, Artibani W, Graefen M et al (2012) Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations. Eur Urol 61(2):341–349. https://doi.org/10.1016/j.eururo.2011.10.033
doi: 10.1016/j.eururo.2011.10.033
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. http://www.ncbi.nlm.nih.gov/pubmed/15273542 . Accessed 15 Jan 2018
Jayram G, Katz MH, Steinberg GD (2010) Radical cystectomy in patients previously treated for localized prostate cancer. Urology 76(6):1430–1433. https://doi.org/10.1016/j.urology.2010.01.048
doi: 10.1016/j.urology.2010.01.048 pubmed: 20381130
Vetterlein MW, Klemm J, Gild P et al (2019) Improving estimates of perioperative morbidity after radical cystectomy using the European Association of urology quality criteria for standardized reporting and introducing the comprehensive complication index. Eur Urol S0302–2838(19):30655
Aziz A, May M, Burger M et al (2014) Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol 66(1):156–163
doi: 10.1016/j.eururo.2013.12.018
Waingankar N, Mallin K, Smaldone M et al (2017) Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy. BJU Int 120(2):239–245
doi: 10.1111/bju.13804

Auteurs

Paolo Gontero (P)

Department of Urology, Molinette Hospital, University of Torino School of Medicine, Turin, Italy.

Francesca Pisano (F)

Department of Urology, Molinette Hospital, University of Torino School of Medicine, Turin, Italy. francescapisano85@gmail.com.
Department of Uro-oncolgy, Fundacio Puigvert, University of Barcelona, Barcelona, Spain. francescapisano85@gmail.com.

Joan Palou (J)

Department of Uro-oncolgy, Fundacio Puigvert, University of Barcelona, Barcelona, Spain.

Steven Joniau (S)

Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Louvain, Belgium.

Maarten Albersen (M)

Oncologic and Reconstructive Urology, Department of Urology, University Hospitals Leuven, Louvain, Belgium.

Renzo Colombo (R)

Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Alberto Briganti (A)

Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Federico Pellucchi (F)

Unit of Urology/Division of Oncology, URI, IRCCS Ospedale San Raffaele, Milan, Italy.

Oscar Rodriguez Faba (OR)

Department of Uro-oncolgy, Fundacio Puigvert, University of Barcelona, Barcelona, Spain.

Bas W van Rhijn (BW)

Netherland Cancer Institute, Amsterdam, The Netherlands.

Elies Fransen van de Putte (EF)

Netherland Cancer Institute, Amsterdam, The Netherlands.

Marko Babjuk (M)

Department of Urology, Motol Hospital, University of Praha, Prague, Czech Republic.

Hanz Martin Fritsche (HM)

Department of Urology, Regensburg University, Regensburg, Germany.

Roman Mayr (R)

Department of Urology, Regensburg University, Regensburg, Germany.

Peter Albers (P)

Department of Urology, Heinrich-Heine-University, Medical Faculty, Düsseldorf, Germany.

Gunter Niegisch (G)

Department of Urology, Heinrich-Heine-University, Medical Faculty, Düsseldorf, Germany.

Julien Anract (J)

Department of Urology, CHU Bichat, Paris, France.

Alexandra Masson-Lecomte (A)

Department of Urology, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France.

Alexandre De la Taille (A)

Department of Urology, Henri Mondor Academic Hospital, Creteil, France.

Morgan Roupret (M)

Department of Urology, Hôpital La Pitié-Salpétrière, Paris 6 University, Paris, France.

Benoit Peyronnet (B)

Department of Urology, Hôpital La Pitié-Salpétrière, Paris 6 University, Paris, France.

Tomaso Cai (T)

Department of Urology, Ospedale S. Chiara, Trento, Italy.

Alfred J Witjes (AJ)

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Max Bruins (M)

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Jack Baniel (J)

Department of Urology, Rabin Medical Centre, Tel Aviv, Israel.

Roy Mano (R)

Department of Urology, Rabin Medical Centre, Tel Aviv, Israel.

Alberto Lapini (A)

Department of Urology, University of Florence, University Hospital of Florence, Florence, Italy.

Francesco Sessa (F)

Department of Urology, University of Florence, University Hospital of Florence, Florence, Italy.

Jaques Irani (J)

Department of Urology, Kremlin-Bicetre Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.

Maurizio Brausi (M)

Department of Urology, Ospedale di Carpi-Modena, Modena, Italy.

Arnulf Stenzl (A)

Department of Urology, University Hospital Tübingen, Tübingen, Germany.

Jeffrey R Karnes (JR)

Department of Urology, Mayo Clinic, Rochester, USA.

Douglas Scherr (D)

Department of Urology, Weill Cornell Medical College, New York, USA.

Padraic O'Malley (P)

Department of Urology, Weill Cornell Medical College, New York, USA.

Benjamin Taylor (B)

Department of Urology, Weill Cornell Medical College, New York, USA.

Shahrokh F Shariat (SF)

Department of Urology, Medical University of Vienna, Vienna, Austria.

Peter Black (P)

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.

Hamidreza Abdi (H)

Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.

Vsevolod B Matveev (VB)

Department of Urology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.

Olga Samuseva (O)

Department of Urology, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia.

Dipen Parekh (D)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Mark Gonzalgo (M)

Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.

Malte W Vetterlein (MW)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Atiqullah Aziz (A)

Department of Urology, University Medical Center Rostock, Rostock, Germany.

Margit Fisch (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

James Catto (J)

Academic Urology Unit, University of Sheffield, Sheffield, UK.

Karl H Pang (KH)

Academic Urology Unit, University of Sheffield, Sheffield, UK.

Evanguelos Xylinas (E)

Department of Urology, CHU Bichat, Paris, France.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH